BioPharma Credit Reports Strong 2025 Results with Increased Income and Dividends

Discount control and dividends: shareholder-friendly moves

BPCR’s Discount Control Mechanism (DCM) – a board policy to buy back shares when the discount stays wide – was triggered in 2025. The company repurchased 56.8 million shares for $50.3 million at an average 86.9 cents. Buybacks at a discount are typically NAV-accretive and supportive for the share price.

Dividends remained a highlight. Three quarterly payments referencing 2025 totalled 6.75 cents; after the year-end, a further 3.20 cents (1.75 cents ordinary + 1.45 cents special) relating to Q4 2025 was paid on 20 March 2026. The company has paid at least 1.75 cents every quarter since 30 June 2018.

By 20 March 2026, the shares were at 94.00 cents, a 6% discount to NAV, narrower than year-end’s 10.1%.

Early 2026 updates: redeployment gathering pace

• UroGen upsized and extended: a new senior term loan now maturing in 2031 at a fixed 8.25% with additional and exit considerations. The company invested an extra $50 million at signing.
• Zenas BioPharma: a new senior secured loan commitment of up to $125 million across five tranches, at 3‑month SOFR + 5.75% (3.25% floor) plus one-time considerations per tranche.
• Paratek: following its combination with Radius Health, BPCR and the private fund each funded $50 million in new debt that replaced the prior Paratek facility. Terms are described as generally comparable with other BPCR loans.
• CytoKinetics notes: 18 million of the 1.75% 2031 convertible notes were sold at an average $1.29, generating a $5.2 million gain.

Unfunded commitments stood at $316.7 million at year-end across Evolus, Geron, Novocure, Precigen, Paratek, UroGen and Zenas, rising to $366.7 million as of 23 March 2026. That, plus the cash balance, indicates a healthy pipeline and capacity to earn.

Why it matters: my take

Positives:

• Income momentum: higher net income per share and fully covered dividends are exactly what income-focused holders want.
• Proactive discount control: meaningful buybacks at a mid‑teens discount for much of the year are shareholder-friendly and accretive.
• Capital recycling: repayments of $616.6 million demonstrate counterparties’ access to capital and support the manager’s strategy of redeploying into fresh, higher‑spread paper.
• Pipeline and post‑period activity: early 2026 deal flow (UroGen, Zenas, Paratek) shows the cash is being put back to work, with attractive coupons and fees.

Watch‑outs:

• Cash drag: 36.7% of NAV in cash at year‑end suppresses near‑term income until fully invested, though early 2026 steps are addressing this.
• Single‑name exposure: Insmed at 18.9% is sizeable. Performance there matters for NAV stability.
• Healthcare pricing risk: several borrowers sell in markets with US government reimbursement exposure. No 2025 regulatory changes were flagged as material, but it remains a standing risk.

Rates, structures and risk: how the book is positioned

BPCR mixes fixed and floating exposure. A number of loans reference SOFR with floors between 2.25% and 3.75%. At 31 December 2025, 1‑ and 3‑month SOFR (3.69% and 3